Chembio, founded in 1985, develops, manufactures, licenses, and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases and other medical conditions. Chembio manufactures three FDA-approved HIV 1/2 tests and three CE-approved tests. Chembio’s FDA and CE-approved DPP® HIV 1/2 Assay works on oral fluid or any blood matrix and is the newest addition to the line of Next Generation DPP (TM) Technology Dual Path Platform products. It detects the presence of HIV 6 days earlier than the current oral fluid rapid test. DPP® technology enables multiplexing and improved sensitivity.
Chembio's FDA and CE-approved HIV 1/2 STAT-PAK® and CE-approved STAT-VIEW® HIV 1/2 Assays for blood are widely used in rapid HIV testing. DPP® HIV-Syphilis, a dual test that uses one patient sample, is available in select countries as is HIV 1/2 STAT-PAK® DIPSTICK, priced for resource-limited markets. Chembio participates in the global HIV rapid testing market with strategic channel partners worldwide. All of our products are manufactured in the U.S.